• DRX-065 in Phase 1 for adrenoleukodystrophy (ALD) & nonalcoholic steatohepatitis (NASH)
  • DRX-164 for oncology¬†& immuno-oncology¬†applications
  • DRX-194 for sickle cell disease
  • DRX-184 for CNS disorders
  • Stabilized, single enantiomers based on several other racemic drugs studied in clinical trials for CNS, metabolic, cancer, autoimmune, anti-inflammatory, and rare / orphan indications.

DeuteRx is interested in pursuing strategic partnerships with major pharmaceutical or biotechnology companies. We have a a large portfolio of stabilized, single enantiomer product opportunities.

Uniquely Differentiated

  • Commercially compelling business strategy
  • Dominating IP position
  • Revolutionary scientific approach
  • Capital efficient virtual company
  • Validated by successful sale of parent company

  • For additional information, please contact:
    • Dr. Sheila DeWitt, President & CEO
    • DeuteRx, LLC
    • 300 Brickstone Square, Suite 201
    • Andover MA 01810
    • Phone: 978-662-5287, Email: info@deuterx.com
Compelling Commercial Strategy
& Large Portfolio of
Product Opportunities